Literature DB >> 9850070

3-(Iodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells.

J D Jiang1, A S Davis, K Middleton, Y H Ling, R Perez-Soler, J F Holland, J G Bekesi.   

Abstract

3-(Iodoacetamido)-benzoylurea (3-IAABU) is a newly synthesized antitubulin compound with a molecular weight of 347. 3-IAABU exhibited anticancer activity in a variety of tumor cell lines with ID90 in the range of 0.015-0.29 microM for leukemic cells and 0.06-0.92 microM for solid tumors. Higher selectivity against malignant cells was observed with 3-IAABU than that with vinblastine and paclitaxel. It inhibits microtubule assembly in tubulin systems either with or without microtubule-associated proteins (ID50 was 0.1 microM and 1.2 microM, respectively) and microtubule depolymerization was not affected, indicating an inhibition of polymerization by binding of 3-IAABU to the heterodimeric subunit of tubulin. 3-IAABU was shown to inhibit the binding of colchicine, a subunit binding compound, but did not inhibit binding of vinblastine and guanosine 5'-triphosphate/guanosine 5'-diphosphate, indicating that colchicine site corresponds to the site that 3-IAABU locates. Tumor cells treated with 3-IAABU showed scattered chromosomes in metaphase. Normal microtubule architecture or spindle apparatus was absent in these cells; instead, punctuated aggregates of tubulin were found by an immunofluorescent staining. Cell cycle analyses showed an accumulation of tumor cells at M phase after a 4-h treatment with 3-IAABU. The phosphorylated bcl-2 representative of an inactivated form of the oncoprotein was found in the cells 12 h after treatment with 3-IAABU. These cells progressed to apoptosis within 16 h. As a new tubulin ligand, 3-IAABU could be a promising agent in cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9850070

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Novel suicide ligands of tubulin arrest cancer cells in S-phase.

Authors:  A Davis; J D Jiang; K M Middleton; Y Wang; I Weisz; Y H Ling; J G Bekesi
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

2.  Microtubule-targeting drugs induce Bcl-2 phosphorylation and association with Pin1.

Authors:  N Pathan; C Aime-Sempe; S Kitada; S Haldar; J C Reed
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

3.  Synthesis of a Potent Vinblastine: Rationally Designed Added Benign Complexity.

Authors:  Oliver Allemann; Manuela Brutsch; John C Lukesh; Daniel M Brody; Dale L Boger
Journal:  J Am Chem Soc       Date:  2016-07-01       Impact factor: 15.419

4.  Ultrapotent vinblastines in which added molecular complexity further disrupts the target tubulin dimer-dimer interface.

Authors:  Daniel W Carney; John C Lukesh; Daniel M Brody; Manuela M Brütsch; Dale L Boger
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-10       Impact factor: 11.205

5.  Microtubule-targeting drugs induce bcl-2 phosphorylation and association with Pin1.

Authors:  N Pathan; C Aime-Sempe; S Kitada; A Basu; S Haldar; J C Reed
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

6.  Identification of Simple Compounds with Microtubule-Binding Activity That Inhibit Cancer Cell Growth with High Potency.

Authors:  Wan Seok Yang; Kenichi Shimada; Darnelle Delva; Milesh Patel; Egberamwen Ode; Rachid Skouta; Brent R Stockwell
Journal:  ACS Med Chem Lett       Date:  2011-10-31       Impact factor: 4.345

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.